Ibio Stock Press Release. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING O
MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. reports third quarter financial results, highlighting progress in its drug pipeline and a recent equity raise. Aug 25, 2025 · The Series G Warrants will expire on the date that is the earlier of (i) 30 trading days following iBio’s public announcement, via a press release on a nationally recognized news wire or the filing of a Current Report on Form 8-K with the Securities and Exchange Commission (the “SEC”), that an Investigational New Drug Application (“IND Aug 25, 2025 · The Series G Warrants will expire on the date that is the earlier of (i) 30 trading days following iBio’s public announcement, via a press release on a nationally recognized news wire or the filing of a Current Report on Form 8-K with the Securities and Exchange Commission (the “SEC”), that an Investigational New Drug Application (“IND May 2, 2025 · iBio, Inc. Nov 12, 2025 · iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update Oct 30, 2025 7:00am EDT Get the latest iBio, Inc. (IBIO) stock news and headlines to help you in your trading and investment decisions. Nov 24, 2025 · The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. This capital infusion will primarily fund the advancement of its preclinical cardiometabolic programs and other pipeline assets, reinforcing its AI-driven approach to precision antibody therapies. Get the latest iBio, Inc. Apr 29, 2025 · Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iBio, Inc. 28, 2017 (GLOBE NEWSWIRE) -- IBIO, INC. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. Oct 21, 2025 · Oral talks on IBIO-610 at ObesityWeek Nov 4–7 and PEGS Europe Nov 11–13 to share preclinical data; a poster on long‑acting anti‑myostatin slated Nov 5. , an AI-driven innovator of precision antibody therapies, today announced it has commenced an underwritten public offering of pre-funded warrants to purchase shares of iBio’ s common Dec 9, 2022 · BRYAN, Texas, Dec. com Media Contacts: Feb 10, 2025 · Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iBio, Inc. Investor Relations ir@ibioinc. . (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the closing of its underwritten public offering of approximately 29. Apr 7, 2025 · Stay up to date with all latest press releases from iBio, Inc. 13, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. Sep 20, 2024 · SAN DIEGO, Sept. Feb 19, 2025 · The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. Pursuant to the agreement, AstralBio will receive an upfront payment of $750,000, which iBio has paid by issuing its common stock to AstralBio. com Jul 7, 2025 · Get the latest iBio, Inc. Investor Relations Aug 19, 2025 · SAN DIEGO, Aug. 7 million shares of its common stock for gross proceeds of $35. “Our fiscal year 2024 was a transformational year for iBio, as we’ve solidified our business and financial position as a next-generation antibody Aug 25, 2025 · AI-driven antibody therapeutics company iBio secures $50M initial funding, with potential for $100M total through warrant exercises. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the closing of a private placement offering with members of its Board of Directors and Officers, totaling over $650,000. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June 30, 2025, and provided a corporate update on its progress. Feb 10, 2025 · Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iBio, Inc. 08, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. specifically disclaims any obligation 3 days ago · Should You Buy or Sell iBio Stock? Get The Latest IBIO Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. Nov 27, 2023 · --iBio, Inc. (IBIO). m. 001 per share effective at 12:01 a. 0 million, before Nov 29, 2017 · NEW YORK, Nov. Eligibility for RubrYc’s investors to receive up to $5 million in development milestones over the next five years, to be paid in common stock or cash, at iBio’s sole discretion.